Natarajan B, Edavalath M, Davies J, Jenkins L, Marshall-Richards N, Evans D, Price DE, Bain SC, Stephens JW.
Department of Diabetes & Endocrinology, Morriston Hospital, ABM University NHS Trust, Swansea, Wales, UK.
Exenatide use in type 2 diabetes is limited in routine clinical practice. We examined a cross-section of 90 patients. Mean weight and HBA(1c) were 114.9+/-20.6 kg, 10.3+/-2.1% at initiation; 108.0+/-15.3 kg (p<0.0001), 9.0+/-2.1% (p<0.001) at 3 months; 109.2+/-18.2 kg (p<0.0001), 9.5+/-2.3% (p=0.08) at 6 months. Exenatide appears effective in reducing HBA(1c) and weight. (c) 2009 Primary Care Diabetes Europe. Published by Elsevier Ltd. All rights reserved.
PMID: 20022310
| < Prev | Next > |
|---|
